The integration of artificial intelligence (AI) and machine learning (ML) into bioprocess development represents a rapid shift in the way discovery, development, optimization, and production of biological products are approached.
The intersection of AI and drug development has ushered in a transformative era, revolutionizing the way researchers approach biomarker/target identification, drug/target interactions, and drug-like molecule design. AI in the life sciences seeks to unravel intricate biological phenomena through systematic assimilation, analysis, and interpretation of expansive and diverse datasets.
Technology is advancing at an extraordinary rate. Industries are benefiting from automation and AI. As technological developments continue to reform the way industries run, the integration of AI and machine learning technologies in the life sciences industry is redefining the traditional approach to commissioning, qualification, and validation (CQV) in pharmaceutical manufacturing.
It is a rare and wonderful legacy to have substantially improved your chosen industry and to have bestowed a name on an initiative that, 30 years later, has become synonymous with best practice. This article celebrates both these pivotal achievements of Anthony (Tony) Trill, who passed in 2024.
In each issue of Pharmaceutical Engineering®, we introduce a member of the ISPE staff who provides ISPE members with key information and services. Meet Laneisha Walker, Manager, Sales Operations.
At first glance, ready-to-use (RTU) primary packaging material (tub systems) give production lines more flexibility and reduce container preparation complexity for aseptic fill/finish operations. However, the aseptic introduction of RTU tub systems requires a thoroughly designed transfer process to avoid contamination of the sterile RTU items and the aseptic core.
The 2025 ISPE Aseptic Conference will be held 17–18 March in Washington, DC, and virtually. Christa Myers, the Conference Chair, offers advice and shares what attendees can expect at the upcoming event.
The 2025 ISPE Facilities of the Future (FoF) Conference will be held 27–28 January in San Francisco, California, US, and virtually. Mike Martin, the conference’s Executive Chair, offers advice and shares what attendees can expect at the upcoming conference.
At the 2024 Facility of the Year Award (FOYA) Celebratory Banquet, ISPE announced the 2024 overall FOYA winner: Eli Lilly Kinsale Limited’s IE2b project. In addition to winning the overall award, Eli Lilly’s IE2b project was recognized as the 2024 Innovation category winner for its innovation in synthetic peptide manufacturing.
Brandi Stockton is Founder of The Triality Group, LLC, where she provides quality, regulatory, and compliance consulting services for life sciences companies. She has more than 20 years of GxP experience, with a specialization in computer systems quality and data integrity. Brandi joined ISPE in 2014. In addition to being chair of the GAMP Americas Community of Practice, she is a member of the...
